治疗原发性骨髓纤维化的JAK2抑制剂研究进展

Advances in the Research of JAK2 Inhibitors for Primary Myelofibrosis

原发性骨髓纤维化是一种骨髓恶性肿瘤疾病,针对其治疗十分困难。许多研究表明,Janus Kinase 2(JAK2)激酶的突变V617F与原发性骨髓纤维化的发生密切相关。近年一些靶向JAK2的抑制剂对致病信号通路的异常调控起到抑制作用,为治疗提供了新的途径。文章将对处于临床阶段的五个JAK2抑制剂进行介绍并详述其研究进展。

Primary Myelofibrosis is a kind of bone marrow cancer which is classified as a myeloproliferative neoplasm. The current treatment for Primary Myelofibrosis is very difficult. Many studies showed that Primary Myelofibrosis was closely related to the mutation V617F in Janus Kinase 2 （JAK2）. Some JAK2 inhibitors have shown the ability of suppressing JAK2 signaling already, which provides new therapeutic method for Primary Myelofibrosis. The article will explore the advances of JAK2 inhibitors which have been approved or in clinical research.